| What are they? |
Active ingredient found in the brand-name medications Mounjaro™ and Zepbound™ |
Active ingredient found in the brand-name medications Ozempic® and Wegovy® |
| Creators |
Eli Lilly and Company. Headquarters located in Indianapolis, Indiana, U.S.A. |
Novo Nordisk A/S. Headquarters located in Bagsvaerd, Denmark. |
| Brand names |
Mounjaro™
Zepbound™
|
Ozempic®
Wegovy®
|
| Drug class |
Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists. |
Glucagon-like peptide-1 (GLP-1) receptor agonist. |
| Conditions for which they are prescribed |
For diabetes under brand name Mounjaro™. For weight loss under brand name Zepbound™
|
For diabetes under brand name Ozempic®. For weight loss under brand name Wegovy® |
| Mechanism of Action |
Activates 2 receptors, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1); leading to increased insulin secretion, delayed gastric emptying and increased insulin sensitivity. |
Activates glucagon-like-peptide-1 (GLP-1) receptors in the brain, regulating appetite and caloric intake. |
| Doses |
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg per injection
|
0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg per injection
|
| Regulations (FDA/DEA) |
Requires prescription. Not a controlled substance. |
Requires prescription. Not a controlled substance. |
| FDA approval year |
Mounjaro™ May 2022. Zepbound™ Nov 2023
|
Ozempic® 2017. Wegovy® 2021
|
| Who is a good candidate for medication? |
Adults with a BMI of 30 or more (obesity category).
Adults with a BMI of 27-29 (overweight category), who also have at least one weight-related comorbid condition such as hypertension, diabetes type 2, or hyperlipidemia. |
Adults with a BMI of 30 or more (obesity category). Adults with a BMI of 27-29 (overweight category), who also have at least one weight-related comorbid condition such as hypertension, diabetes type 2, or hyperlipidemia. Pediatrics, 12 years and older with a BMI in the 95th percentile or greater. |
| How often should it be injected? |
Once weekly, at any time of the day. |
Once weekly, at any time of the day. |
| Method of administration |
Subcutaneous injection |
Subcutaneous injection |
| Average weight loss |
At 15 mg (max dose), patients lose about 20.9% of their body weight. With 1 in 3 losing up to 26.6%. |
At 2.4 mg (max dose), patients lose about 15% of their body weight. With 1 in 4 losing up to 20%. |
| Common side effects |
nausea, vomiting, diarrhea, constipation, abdominal pain, heartburn, other possible side effects not listed here.
|
nausea, vomiting, diarrhea, constipation, abdominal pain, heartburn, other possible side effects not listed here. |
| Contraindications |
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MENS2) or in case of hypersensitivity to drug. |
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MENS2) or in case of hypersensitivity to drug. |
| Price of brand name |
Approximately $1057.00 for 1 carton of 4 prefilled pens (1 month supply). Zepbound™ approved by FDA on November 2023, drug not yet available for prescribing; anticipated availability December 2023. |
Approximately $1,386.00 for 1 carton of 4 prefilled pens (1 month supply). |
| Price with us |
$499.00 for Compounded Tirzepatide. Includes consultation and shipping. |
$299.00 for Compounded Semaglutide. Includes consultation and shipping. |
